

Haematologica  
HAEMATOL/2018/209932  
Version 3

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

Riccardo Bruna, Fabio Benedetti, Carola Boccomini, Caterina Patti, Anna Maria Barbui, Alessandro Pulsoni, Maurizio Musso, Anna Marina Liberati, Guido Gini, Claudia Castellino, Fausto Rossini, Fabio Ciceri, Delia Rota-Scalabrini, Caterina Stelitano, Francesco Di Raimondo, Alessandra Tucci, Liliana Devizzi, Valerio Zoli, Francesco Zallio, Franco Narni, Alessandra Dondi, Guido Parvis, Gianpietro Semenzato, Francesco Lanza, Tommasina Perrone, Francesco Angrilli, Atto Billio, Angela Gueli, Barbara Mantoan, Alessandro Rambaldi, Alessandro Massimo Gianni, Paolo Corradini, Roberto Passera, Marco Ladetto, and Corrado Tarella

Collaborative Groups: GITMO (Gruppo Italiano Tapianto Midollo Osseo) (IIL (Intergruppo Italiano Linfomi) )

Disclosures: - This work was supported in part by the Ministero Italiano Università e Ricerca (MIUR), Rome, Italy (grant PRIN 2010-2011, pr. N.: 2010B5B2NL), and by Banca del Piemonte (Torino, Italy). - The initial clinical trial (March 2000 - May 2005) was made possible by Compagnia di San Paolo (Torino, Italy), Regione Piemonte (Torino, Italy), and by Roche (Milan, Italy), which provided free rituximab for all patients. - We are indebted to GITMO (Gruppo Italiano Tapianto Midollo Osseo) and to IIL, now merged into FIL (Fondazione Italiana Linfomi) for their fundamental participation in the development and completion of the study. Conflict of interest: M. Ladetto: honoraria from Abbvie, Acerta, Amgen Archigen Celgene ADC therapeutics, Gilead Novartis J&J Roche Roche Diagnostics Sandoz Takeda. Francesco Di Raimondo: honoraria from Roche Alessandro Rambaldi: Travel support, sponsored lectures and advisory board meetings: Roche, Amgen, Pfizer, Novartis, Celgene. Corrado Tarella: Travel support from Amgen and Ce

Contributions: R.B. and C.T. conceived the present study; the initial trial was designed by A.M.G., P.C., M.L. and C.T. (along with A. Pileri, now retired); F.B., C.B., C.P., A.M.B., A. P., M.M., A.M.L., G.G., C.C., F.R., F.C., D.R.S., C.S., F.D.R., A.T., L.D., V.Z., F.Z., F.N., A.D., G.P., G. S., F.L., T.P., F.A., A.B., A.R., A.M.G., P.C., M.L., and C.T. were involved in patient enrollment and care and clinical data updates; R.B., A.G., R. P. and C.T. performed data collection and analysis; molecular analysis was performed by B.M. and M.L. (responsible); R.P. performed the statistical analyses; CT wrote the paper; R.B., A.M.G., A.R., P.C., R.P., M.L. and C.T. supervised the analyses and reviewed the manuscript.